{"id":62300,"date":"2026-04-04T21:22:26","date_gmt":"2026-04-04T13:22:26","guid":{"rendered":"https:\/\/flcube.com\/?p=62300"},"modified":"2026-04-04T21:22:27","modified_gmt":"2026-04-04T13:22:27","slug":"bio-thera-solutions-gains-nmpa-clearance-for-phase-i-ii-trial-of-pd-1-biosimilar-bat3306-combined-with-trop2-adc-bat8008-in-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62300","title":{"rendered":"Bio-Thera Solutions Gains NMPA Clearance for Phase I\/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors"},"content":{"rendered":"\n<p><strong>Bio-Thera Solutions, Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688177:SHA\">SHA: 688177<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has approved its investigational new drug (IND) application to initiate a clinical study evaluating the combination of <strong>BAT3306<\/strong>, a <strong>biosimilar of Merck\u2019s Keytruda (pembrolizumab)<\/strong>, and <strong>BAT8008<\/strong>, the company\u2019s proprietary <strong>Trop2-targeting antibody-drug conjugate (ADC)<\/strong>, in patients with <strong>advanced solid tumors<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profiles-amp-rationale-for-combination\">Drug Profiles &amp; Rationale for Combination<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Mechanism &amp; Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>BAT3306<\/strong><\/td><td>PD-1 monoclonal antibody biosimilar to <strong>Keytruda<\/strong>; designed to replicate efficacy and safety of the reference product at lower cost<\/td><\/tr><tr><td><strong>BAT8008<\/strong><\/td><td><strong>Trop2-directed ADC<\/strong> featuring:<br>\u2022 Potent cytotoxic payload<br>\u2022 Strong <strong>bystander effect<\/strong> (kills neighboring antigen-negative tumor cells)<br>\u2022 <strong>High plasma stability<\/strong> and <strong>extremely low payload detachment rate<\/strong><br>\u2022 Favorable non-clinical safety profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The combination leverages <strong>immune checkpoint inhibition<\/strong> (BAT3306) to enhance T-cell activity alongside <strong>targeted tumor cell killing<\/strong> (BAT8008), with the bystander effect potentially overcoming heterogeneous Trop2 expression\u2014a common challenge in solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-strategic-significance\">Clinical &amp; Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cost-Efficient Innovation:<\/strong> By pairing an in-house <strong>Keytruda biosimilar<\/strong> with a novel ADC, Bio-Thera aims to deliver a high-value combo regimen without reliance on external partners or premium-priced originator drugs.<\/li>\n\n\n\n<li><strong>Trop2 as High-Priority Target:<\/strong> Trop2 is overexpressed in multiple carcinomas (e.g., NSCLC, triple-negative breast cancer, urothelial), making BAT8008 a versatile backbone for combination strategies.<\/li>\n\n\n\n<li><strong>China-First Development:<\/strong> The trial reinforces Bio-Thera\u2019s dual focus on <strong>global biosimilars<\/strong> and <strong>innovative biologics<\/strong>, positioning it as a hybrid biopharma player in China\u2019s evolving oncology landscape.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-context\">Competitive Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Race Heats Up:<\/strong> Over 20 Trop2 ADCs are in clinical development globally; BAT8008\u2019s <strong>low detachment rate<\/strong> and <strong>bystander potency<\/strong> may differentiate it from competitors like Daiichi Sankyo\u2019s datopotamab deruxtecan.<\/li>\n\n\n\n<li><strong>Biosimilar Leverage:<\/strong> Unlike innovators paying royalties for combo trials with Keytruda, Bio-Thera controls both assets\u2014accelerating development and improving margin potential.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, mechanism of action, and competitive positioning. Actual results depend on trial outcomes, regulatory decisions, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688177_20260403_AHVF.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688177_20260403_AHVF.\"><\/object><a id=\"wp-block-file--media-c060fcc5-3736-41d1-95c5-31216d6bef75\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688177_20260403_AHVF.pdf\">688177_20260403_AHVF<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688177_20260403_AHVF.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-c060fcc5-3736-41d1-95c5-31216d6bef75\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China\u2019s National Medical Products Administration (NMPA) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,289,62,2675,18,1055],"class_list":["post-62300","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-bio-thera-solutions","tag-clinical-trial-approval-initiation","tag-merck-sharp-dohme","tag-pd-1-l1","tag-sha-688177"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio-Thera Solutions Gains NMPA Clearance for Phase I\/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China\u2019s National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application to initiate a clinical study evaluating the combination of BAT3306, a biosimilar of Merck\u2019s Keytruda (pembrolizumab), and BAT8008, the company\u2019s proprietary Trop2-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62300\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Thera Solutions Gains NMPA Clearance for Phase I\/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China\u2019s National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application to initiate a clinical study evaluating the combination of BAT3306, a biosimilar of Merck\u2019s Keytruda (pembrolizumab), and BAT8008, the company\u2019s proprietary Trop2-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62300\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-04T13:22:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-04T13:22:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62300#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62300\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Thera Solutions Gains NMPA Clearance for Phase I\\\/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors\",\"datePublished\":\"2026-04-04T13:22:26+00:00\",\"dateModified\":\"2026-04-04T13:22:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62300\"},\"wordCount\":342,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Bio-Thera Solutions\",\"Clinical trial approval \\\/ initiation\",\"Merck Sharp &amp; Dohme\",\"PD-1\\\/L1\",\"SHA: 688177\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62300#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62300\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62300\",\"name\":\"Bio-Thera Solutions Gains NMPA Clearance for Phase I\\\/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-04T13:22:26+00:00\",\"dateModified\":\"2026-04-04T13:22:27+00:00\",\"description\":\"Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China\u2019s National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application to initiate a clinical study evaluating the combination of BAT3306, a biosimilar of Merck\u2019s Keytruda (pembrolizumab), and BAT8008, the company\u2019s proprietary Trop2-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62300#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62300\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62300#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Thera Solutions Gains NMPA Clearance for Phase I\\\/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Thera Solutions Gains NMPA Clearance for Phase I\/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China\u2019s National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application to initiate a clinical study evaluating the combination of BAT3306, a biosimilar of Merck\u2019s Keytruda (pembrolizumab), and BAT8008, the company\u2019s proprietary Trop2-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62300","og_locale":"en_US","og_type":"article","og_title":"Bio-Thera Solutions Gains NMPA Clearance for Phase I\/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors","og_description":"Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China\u2019s National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application to initiate a clinical study evaluating the combination of BAT3306, a biosimilar of Merck\u2019s Keytruda (pembrolizumab), and BAT8008, the company\u2019s proprietary Trop2-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors.","og_url":"https:\/\/flcube.com\/?p=62300","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-04T13:22:26+00:00","article_modified_time":"2026-04-04T13:22:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62300#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62300"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Thera Solutions Gains NMPA Clearance for Phase I\/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors","datePublished":"2026-04-04T13:22:26+00:00","dateModified":"2026-04-04T13:22:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62300"},"wordCount":342,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Bio-Thera Solutions","Clinical trial approval \/ initiation","Merck Sharp &amp; Dohme","PD-1\/L1","SHA: 688177"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62300#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62300","url":"https:\/\/flcube.com\/?p=62300","name":"Bio-Thera Solutions Gains NMPA Clearance for Phase I\/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-04T13:22:26+00:00","dateModified":"2026-04-04T13:22:27+00:00","description":"Bio-Thera Solutions, Ltd. (SHA: 688177) announced that China\u2019s National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application to initiate a clinical study evaluating the combination of BAT3306, a biosimilar of Merck\u2019s Keytruda (pembrolizumab), and BAT8008, the company\u2019s proprietary Trop2-targeting antibody-drug conjugate (ADC), in patients with advanced solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62300#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62300"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62300#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Thera Solutions Gains NMPA Clearance for Phase I\/II Trial of PD-1 Biosimilar BAT3306 Combined with Trop2 ADC BAT8008 in Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62300"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62300\/revisions"}],"predecessor-version":[{"id":62384,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62300\/revisions\/62384"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}